Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US98978V1035
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG0039320N9
ZTS
Zoetis Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—Specialty & Generic · THEMEFOLIO: $BIRD
NAME
Zoetis Inc
ISIN
US98978V1035
TICKER
ZTS
MIC
XNYS
REUTERS
ZTS.N
BLOOMBERG
ZTS US
Mon, 01.06.2026       Zoetis
US98978V1035

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”), have until July 27, 2026 to seek appointment as lead plaintiff of the Zoetis class action lawsuit. Captioned City of Ann Arbor Retiree...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.05.2026       Zoetis
US98978V1035

Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased Zoetis, Inc. (NYSE: ZTS) shares pr...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federa...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Zoetis
US98978V1035

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Zoetis
US98978V1035

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. (“Zoetis” or “the Company”) (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Zoetis
US98978V1035

NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026,...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Zoetis
US98978V1035

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026. Zoetis describes itself as an “animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digi...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Zoetis
US98978V1035

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”). Zoetis investors have until July 27, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVE...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Zoetis
US98978V1035

SAN DIEGO, May 28, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), have until July 27, 2026 to seek appointment as lead plaintiff of the Zoetis class action lawsuit. Captioned City of Ann...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Zoetis
US98978V1035

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 28.05.2026       Zoetis
US98978V1035

SAN DIEGO, May 28, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026. Zoetis is an animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Zoetis
US98978V1035

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026. Zoetis is an animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutio...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Zoetis
US98978V1035

Labaton Keller Sucharow LLP (“Labaton”) has filed a securities class action lawsuit (the “Action”) on behalf of its client the City of Ann Arbor Retiree Health Care Benefit Plan & Trust (“Ann Arbor RHC”) against Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) and certain of its executives (collectively, “Defendants”). The Action, which is...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Zoetis
US98978V1035

Zoetis slashed full-year guidance, triggering a roughly 21.5% single-session stock decline that erased significant shareholder value. NEW YORK, May 27, 2026 /PRNewswire/ -- Zoetis Inc. (NYSE: ZTS) shareholders lost approximately 21.5% of their investment -- roughly $23.91 per share -- on May 7, 2026, when the company reported Q1 2026 results that...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Zoetis
US98978V1035

Law Offices of Howard G. Smith continues its investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOETIS INC. (ZTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Zoetis
US98978V1035

The Law Offices of Frank R. Cruz continues its investigation of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.W...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Zoetis
US98978V1035

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO INQUIRE AB...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2026       Zoetis
US98978V1035

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences. Stifel 2026 Jaws & Paws Conference on Thursday, May 28, 2026 at 3:00 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 1:20 p.m. CT Interested parties...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, July 20, 2026. About Zoetis Zoetis is the world’s leading animal health...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 20.05.2026       Zoetis
US98978V1035

Zoetis CEO told investors the macro environment would "gradually improve" and guided for 3%-5% organic revenue growth in FY 2026 -- weeks before the company slashed guidance and shares lost a fifth of their value. NEW YORK, May 20, 2026 /PRNewswire/ -- Investors in Zoetis Inc. (NYSE: ZTS) lost approximately 21.5% of their holdings on May 7, 2026,...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       Zoetis
US98978V1035

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC....
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       Zoetis
US98978V1035

Law Offices of Howard G. Smith announces an investigation on behalf of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOETIS INC. (ZTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       Zoetis
US98978V1035

The Law Offices of Frank R. Cruz announces an investigation of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZOETIS INC. (ZTS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOS...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Zoetis
US98978V1035

Zoetis slashed full-year guidance, triggering a roughly 21.5% single-session stock decline that erased significant shareholder value.NEW YORK, May 13, 2026 /PRNewswire/ -- Zoetis Inc. (NYSE: ZTS) shareholders lost approximately 21.5% of their investment -- roughly $23.91 per share -- on May 7, 2026, when the company reported Q1 2026 results that f...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.05.2026       Zoetis
US98978V1035

MILWAUKEE, May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Zoetis (NYSE: ZTS). The investigation results from inaccurate statements Zoetis may have made regarding its financial statements, business operations and prospects....
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the first quarter of 2026. The company reported revenue of $2.3 billion for the first quarter of 2026, an increase of 3% compared with the first quarter of 2025 and flat on an organic operational1 basis. Net income for the first quarter of...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 20.04.2026 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 20.04.2026...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may acc...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 10:30 a.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations....
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside chats at the following investor conferences. Leerink Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) the world’s leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ: NEOG) (“Neogen”) to acquire Neogen’s animal genomics business for $160 million, subject to customary closing adjustments. This acquisition aligns directly with Zoetis’ strategy to drive futu...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company. Interested parties can access the live audio webcast by visiting https://investor.zoetis.com/events-p...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year 2025 and provided full year guidance for 2026. The company reported revenue of $2.4 billion for the fourth quarter of 2025, an increase of 3% compared with the fourth quarter of 2024. On an organic operati...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.02.2026       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world’s leading animal health company,...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 20.01.2026 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 20.01.2026...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 20.01.2026 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 20.01.2026...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.12.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors a...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other intereste...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.12.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that it has priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securiti...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. “The pace of animal health innovation...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Investors and other intere...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025. The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 20...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.11.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed K...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 31.10.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 31.10.2025...
Read more
Zoetis
Technical Analysis Termsheets Terminal
Permalink